Andersons pediatric cardiology 2373
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (75.77 KB, 3 trang )
Proepicardialorgan,60f
Prognosis,researchstudieson,criticalappraisalof,420
Programmedstimulation,359
Prophylacticagents,infibrinolysis,1289–1290
Prophylacticantiplatelettherapy,forinterstagemanagement,1309
Prophylactictreatment,forhemodynamicallysignificantarterialduct,199
Prophylaxis,forinfectiveendocarditis,1059–1061
cost-effectiveness,1061
fordentalprocedures,1059,1060b
fornondentalprocedures,1059
recommendationsof2007-2008compliance,1060
recommendationsof2007-2008(forFrance2002)Impact,1060,1060t
Propionicacidemia,cardiacinvolvementin,1097
Propofol,forinducingdeepsedationandgeneralanesthesia,1549
Proportions,definitionof,173,174t
Propranolol
foratrialtachyarrhythmias,139t
forhypertension,1140t
forthyrotoxicosis,142
Proproteinconvertasesubtilisin/kexintype9inhibitors,433
Propylthiouracil
foratrialtachyarrhythmias,139t
forthyrotoxicosis,142
ProspectiveAssessmentafterPediatricCardiacAblation,1511t–1514t
Prostacyclin
incontrolofcirculation,1358
inendothelialfunction,1356
forpulmonaryhypertension,1389
Prostaglandin
forcongenitallymalformedhearts,209
prostaglandinE1,feedingand,1498–1499
Prostanoids,forpulmonaryhypertension,1389
Prostheticheartvalvesinpregnancy,1447–1448,1447t
Proteasomalactivity,70
Protein
aggregation,70f
synthesisanddegradationof,cardiomyocyte,68–71,69f–70f
turnover,69
Proteinkinasemutations,adenosinemonophosphate-activated,hypertrophic
cardiomyopathyand,1148
Protein-losingenteropathy,inFontan-associatedliverdisease,1333–1334
Proteoglycans,1356
Pseudo-Hurlersyndrome,cardiacinvolvementin,1092
Pseudotamponadephysiology,219–220
Psychologicalaspectsofpediatriccardiacdisease,1455–1464
child,1455–1459
Psychologicalhealth,inFontan-associatedliverdisease,1335
Psychologicaloutcomes,forchildrenwithcardiacdisease,1457–1459
Psychologicalresponses,ofparentsandfamiliesofchildrenwithcardiac
disease,1461–1462
Psychologicalstressofpediatriccardiacdisease,developmentalapproachto,
1455–1456,1457t–1458t
Psychosocialadjustment,1458
Psychosocialissues,followingcardiactransplantation,1238
Pulmonaryandsystemicbloodflow,balancing,1264f
Pulmonaryarterialsling,877–900,893f
clinicalmanifestationsof,892
diagnosticinvestigationfor,892–893,894f
outcomesfor,898
repairof,898,898f–899f
Pulmonaryarterialstenosis,778–779
interventionaltechniquesfor,271–273
balloonangioplastyand,272,272f
stentingand,272–273,273f
Pulmonaryarteries
arterialswitchproceduresand,694–695,694f
characteristicpatternsof,658,658f
indiagnosticcatheterization,247–248
discontinuous,248
hypoplasticbranch,248,248f
normalpressures,248
saturations,247–248
intrapericardial,morphologyof,655
morphologyof,655–658
three-dimensionalechocardiographyof,314t
Pulmonaryarteriovenousmalformations,931–936
clinicalfeaturesof,933
indiagnosticcatheterization,248–249,249f
incidenceof,931–932,931f–933f
investigationin,934
managementof,934–936,934f–936f
pulmonaryangiographyin,934
screeningfor,934
Pulmonaryartery
anomalousoriginof,fromtheascendingaorta,909
channelsfromtheascendingaortato,908–909,908f–909f
isolatedoriginofthesubclavianarteryfrom,882–883,887f
Pulmonaryarterybanding,1280,1280f
Pulmonaryarterycatheterization,foracutecirculatoryfailure,1181
Pulmonaryatresia
indiagnosticcatheterization,247,247f
withintactventricularseptum,803–818,804f
angiographyin,811–812,812f
cardiaccatheterizationin,811–812,812t
